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Abstract
Background: Stigmatization is an important issue in the treatment and course of schizophrenia. The maintenance of stigmatizing attitudes may be related to 
socio-cultural factors. Objectives: To compare stigmatizing attitudes of mental health professionals in the culturally diverse countries Brazil and Switzerland. 
Methods: We analyzed data of two broad stigmatization surveys from Switzerland and Brazil by focusing on the social distance and attitudes of mental health 
professionals towards the acceptance of side effects of psychopharmacological treatment. Results: Swiss mental health professionals showed significantly higher 
levels of social distance than their Brazilian counterparts. There was also a weak effect of age as well as an interaction effect between origin and age. With respect 
to the acceptance of side effects, the effect of origin was rather weak. With the exception of drug dependence, Swiss professionals’ acceptance of long-lasting 
side effects was significantly higher than for their counterparts in Brazil. Discussion: The strong association between origin and social distance may be related 
to the socio-cultural background of the mental health professionals. In comparison with Switzerland, Brazil is very heterogeneous in terms of ethnicity and 
socio-economic structure. The distinct acceptance of side effects may additionally be related to the more sophisticated medicaments (i.e. new generation of 
antipsychotic drugs) commonly used in Switzerland. 
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Resumo
Contexto: A estigmatização é uma questão importante no tratamento e no curso da esquizofrenia. A manutenção de atitudes estigmatizantes pode estar relacio-
nada a fatores socioculturais. Objetivos: Comparar atitudes estigmatizantes de profissionais de saúde mental em países culturalmente diversos: Brasil e Suíça. 
Métodos: Foram analisados dados de duas grandes pesquisas sobre o estigma na Suíça e no Brasil, focando-se no desejo de distância social em relação a indivíduos 
com esquizofrenia e atitudes de profissionais de saúde mental em relação à aceitação de efeitos colaterais do tratamento psicofarmacológico. Resultados: Profis-
sionais de saúde mental suíços apresentaram níveis significativamente mais elevados de distância social do que suas contrapartes brasileiras. Houve também um 
efeito fraco de idade, bem como um efeito da interação entre a origem e a idade. Com relação à aceitação de efeitos colaterais, a influência da origem foi bastante 
fraca. Com exceção do risco de dependência dos psicotrópicos, a aceitação dos profissionais suíços a efeitos colaterais de longa duração foi significativamente 
maior do que a de seus colegas no Brasil. Conclusões: A forte associação entre origem e distância social pode estar relacionada à formação sociocultural dos 
profissionais de saúde mental; em comparação com a Suíça, o Brasil é muito heterogêneo em termos de estrutura étnica e socioeconômica. A aceitação de efeitos 
colaterais pode também estar relacionada com os medicamentos mais sofisticados (ou seja, drogas antipsicóticas de nova geração) comumente usados na Suíça.
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Introduction
Stigma towards individuals with schizophrenia is known to worsen 
the outcome of the disorder. Studies have shown that depression, 
self-confidence and quality of life, for example, are worst for those 
who experience stigma than for those who do not1,2. This led to 
stigma being intensively studied over the past two decades as well 
as to the launch and evaluation of several anti-stigma campaigns3,4.
As part of the research conducted on stigma, there has been 
much debate as to which measures should be adopted to reduce 
prejudice. For instance, some authors have proposed that the stigma 
against the mentally ill be fought with a three-pronged strategy: 
contact, information and protest5,6. On the other hand, assessments 
about the deinstitutionalization process in the United States have 
shown that greater contact with the mentally ill, in fact, increased 
the stigma towards them by the general population7. As for biased 
information or misinformed opinion, they have been demonstrated 
to be another source of stigma stimulation; for instance, greater 
media coverage of crimes committed by individuals with mental 
disorders and the stereotypical association between this population 
and dangerousness or aggressiveness has been shown to contribute 
to a large extent to increasing prejudice towards such individuals8. 
However, this contrasts with the view held by some that mental 
health (MH) professionals (who by the very nature of their occupa-
tion are people in constant contact with psychiatric patients) can use 
information to label individuals and thus decrease social distance9. 
Some other studies have shown that the attitude of MH professionals, 
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a key population in promoting views that do not stigmatize the 
mentally ill, is sometimes more prejudicial than the attitude of the 
general population10,11. 
Broad, worldwide anti-stigma initiatives have encountered some 
difficulty in reaching full efficacy12,13. This is because stigma appears 
to be a complex social phenomenon14, deeply entrenched in society, 
and one that manifests itself in a heterogeneous way, in keeping with 
the specific characteristics of each socio-cultural environment. If such 
initiatives are to have the desired effect on MH professionals who 
play a fundamental role in disseminating appropriate knowledge 
and attitudes towards the mentally ill, issues such as the following 
need to be examined: do the socio-cultural factors of each specific 
environment in which these professionals work play a role in stigma 
manifestations, and to what extent does the setting influence stigma? 
Thus, the aim of this study was to assess this transcultural issue by 
comparing two samples of MH professionals from distinct countries, 
one from Switzerland, the other from Brazil, for their social distance 
to individuals with schizophrenia and their acceptance of side effects 
of psychopharmacological treatment of these patients. 
Methods
Samples and procedure
For Switzerland we re-analyzed data from the study “health and 
illness in people with mental disorders – a professional perspec-
tive”10,11,15. For that survey, all 32 psychiatric institutions of the 
German-speaking part of Switzerland were included in data collec-
tion. MH professionals were selected through the following process 
1) an outline of the project sent to the executives of all 32 institutions, 
2) a presentation of the study delivered at each participating institu-
tion, and 3) distribution of a handout with an application form to 
every MH professional in the participating institutions. In all 3,088 
mental health professionals representative of the German-speaking 
part of Switzerland were approached, and 1,073 subjects (response 
rate 34.7%) agreed to participate in a computer-assisted telephone 
interview (CATI). Specially trained psychology students conducted 
CATI under supervision between April 2003 and April 2004. Three 
case vignettes were presented for the purpose of com paring stigma-
tization between different patients groups. The first case vignette 
described a patient with depression, the second a patient with 
schizophrenia and the third described a person in a changing life 
situation without any psychiatric symptoms. Further details of the 
sampling procedure have been provided elsewhere10. For the present 
study we used only participants that responded to the questions after 
introduction of the case vignette of schizophrenia, which reduced 
the sample size to 383 subjects. 
The Brazilian participants were recruited and surveyed through 
a face-to-face interview during the Brazilian Congress of Psychiatry 
held in Sao Paulo in November 2009 by the Brazilian Association 
of Psychiatry. This national congress is considered to attract a large 
audience, with normally over 5,000 participants from all over the 
country and many visitors from abroad. Since Sao Paulo is Brazil’s 
largest city and it has many MH professionals, in the year the 
study was conducted some 6,500 individuals were present at the 
meeting. A research institute was hired to perform the interviews. 
Fifty interviewers were selected and trained by the investigators of 
this study. In the Brazilian sample of mental health professionals 
the case vignette used in Switzerland describing a patient with 
schizophrenia was replaced with the expression “a person diagnosed 
with schizophrenia” to keep the duration of the interview as short 
as possible. During the four days of the conference, overall 2,549 
participants were invited to participate in the face-to-face inter-
views. Of these, 954 persons refused to participate or to complete 
the entire questionnaire, which reduced the sample size to 1,595 
subjects. A further three participants were excluded because they 
were nationals of Venezuela, thus leading to a final sample number 
of 1,592 Brazilian MH professionals (response rate 62.5%). More 
details have been provided elsewhere16. 
Instrument and measures
The questionnaire applied in both samples has been used in pre-
vious attitude-surveys in Switzerland10,11,15,17 and Brazil18. Along with 
socio-demographic information the instrument includes questions 
on stereotypes, social distance and prejudice against mentally ill 
people as well as recommendations on treatment. For the present 
study, we adapted 10 items related to the acceptance of side effects 
of psychopharmacological treatment from the survey of Angermeyer 
et al.19 and 6 items of the Social Distance Scale20. The original Social 
Distance Scale consists of seven questions, but the item “would you 
rent a room to a person with schizophrenia” was only provided in 
the Swiss sample, as in Brazil it is quite uncommon to rent a room 
to another person. 
The Social Distance Scale assesses a respondent’s willingness to 
interact with a person with a mental disorder. The response scale in 
the Swiss survey ranged from 1 “certainly yes” to 5 “definitely no”. 
The Brazilian interview used a 3-point Likert scale with 1 standing 
for “certainly yes”, 2 for “maybe” and 3 for “definitely not”. As a result, 
the Swiss data had to be recoded to correspond to the Brazilian data. 
We matched the values 1 and 2 of the Swiss data with the value 1 of 
the Brazilian data, the value 3 of the Swiss data with the value 2 of 
the Brazilian data and, finally, the values 4 and 5 of the Swiss data 
with the value 3 of the Brazilian data. The internal consistency of the 
scale was good (Cronbach’s a = 0.742).
The acceptance of side effects of psychopharmacological treat-
ment measures the attitude, for how long a person with schizophrenia 
should accept various side effects of psychopharmacological treat-
ment. Answers had to be chosen from a 3-point Likert scale ranging 
from 1 “should not accept”, 2 “should accept 2-3 weeks” and 3 “should 
accept more than 3 weeks (i.e. in the long turn)”. The internal consis-
tency of that scale was also good (Cronbach’s a = 0.742).
Statistical analyses
First, bivariate associations between attitudes towards persons with 
schizophrenia and origin of MH professionals were conducted with 
cross-tabulations. Significance levels were indicated with Pearson 
Chi-square test statistics. Second, continuous variables for social 
distance and acceptance of side effects of psychopharmacological 
treatment were obtained by computing the sum-score of all response 
items in a given category. Afterwards, both scales were standardized 
by applying the z-transformation. High values indicated increased 
social distance and acceptance of side effects, respectively. Third, for 
both continuous measures a separate multivariate model was carried 
out using a three factorial ANOVA. Origin, sex, age and their first 
and second order interaction effects were entered as the independent 
variables. Two-tailed significance tests were applied. 
All statistical analyses were conducted with SPSS version 19 for 
Macintosh.
Results 
The final Swiss sample used for the present study consisted of 140 
males (36.6%) and 243 females (63.4%), and the mean age was 40.8 
years (SD = 9.2). Furthermore, the sample comprised 67 psychiatrists 
(17.5%), 27 psychologists (7.0%), 240 attendants (62.7%), and 49 
social workers and other physicians/therapists (12.8%). The Brazilian 
sample of MH professionals consisted of 853 males (53.6%) and 
739 (46.4%) females and the mean age was 42.8 years (SD = 12.7). 
The sample comprised 1,414 psychiatrists (88.8%), 44 psychologists 
(2.8%), 11 attendants (0.7%) and 123 social workers and other phy-
sicians/therapists (7.7%). 
In the bivariate analyses for the single items of social distance 
from persons with schizophrenia, Swiss MH professionals reported 
significantly more social distance than Brazilian MH professionals 
(see table 1). Bivariate results for the acceptance of side effects of 
psychopharmacological treatment are reported in table 2. With the 
exception of drug addiction, Brazilian MH professionals were more 
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Table 1. Social distance against persons with schizophrenia: frequency and percentage of response categories in association with origin of the mental 
health professionals
Swiss Brazil c2 (Sig.)
 Would you move next door to a  person with
 schizophrenia?
Certainly yes
Maybe
Definitely not
283 (73.9%)
60 (15.7%)
40 (10.4%)
1210 (76.1%)
319 (20.1%)
62 (3.9%)
28.888 (0.000)
Would you like your child or other relative to marry 
a person with schizophrenia?
Certainly yes
Maybe
Definitely not
131 (35.4%)
128 (34.6%)
111 (30.0%)
398 (25.0%)
869 (54.6%)
325 (20.4%)
48.080 (0.000)
Would you trust a person with schizophrenia to 
take care of your children?
Certainly yes
Maybe
Definitely not
49 (12.9%)
79 (20.7%)
253 (66.4%)
457 (28.7%)
805 (50.6%)
329 (20.7%)
309.059 (0.000)
Would you like to start work with a person with 
schizophrenia?
Certainly yes
Maybe
Definitely not
163 (43.1%)
56 (14.8%)
159 (42.1%)
1275 (80.1%)
297 (18.7%)
20 (1.3%)
619.530 (0.000)
Would you introduce a friend of yours to a person 
with schizophrenia?
Certainly yes
Maybe
Definitely not
176 (46.1%)
82 (21.5%)
124 (32.5%)
1398 (87.8%)
168 (10.6%)
26 (1.6%)
481.583 (0.000)
Would you recommend a person with schizophrenia 
for a job?
Certainly yes
Maybe
Definitely not
72 (18.9%)
101 (26.5%)
208 (54.6%)
621 (39.1%)
891 (56.1%)
77 (4.8%)
614.637 (0.000)
Table 2. Acceptance of side effects of psychopharmacological treatment: frequency and percentage of response categories in association with origin of 
the mental health professionals
Swiss Brazil c2 (Sig.)
 Dry mouth Not accept
Accept 2-3 weeks
Accept in the long term
12 (3.2%)
168 (44.2%)
200 (52.6%)
79 (5.0%)
840 (53.0%)
665 (42.0%)
14.750 (0.001)
 Transpiration Not accept
Accept 2-3 weeks
Accept in the long term
19 (5.0%)
227 (60.1%)
132 (34.9%)
197 (12.4%)
930 (58.6%)
459 (28.9%)
18.908 (0.000)
 Fatigue Not accept
Accept 2-3 weeks
Accept in the long term
24 (6.3%)
280 (73.9%)
75 (19.8%)
346 (21.8%)
1006 (63.5%)
233 (14.7%)
49.103 (0.000)
 Sexual impairment Not accept
Accept 2-3 weeks
Accept in the long term
49 (13.2%)
206 (55.7%)
115 (31.1%)
322 (20.4%)
736 (46.6%)
522 (33.0%)
13.508 (0.001)
 Restlessness Not accept
Accept 2-3 weeks
Accept in the long term
133 (35.3%)
218 (57.8%)
26 (6.9%)
765 (48.3%)
714 (45.1%)
104 (6.6%)
21.724 (0.000)
 Weight gain Not accept
Accept 2-3 weeks
Accept in the long term
66 (17.5%)
184 (48.8%)
127 (33.7%)
553 (35.0%)
523 (33.1%)
506 (32.0%)
50.527 (0.000)
 Movement disorder Not accept
Accept 2-3 weeks
Accept in the long term
226 (59.6%)
141 (37.2%)
12 (3.2%)
1159 (73.2%)
385 (24.3%)
39 (2.5%)
27.503 (0.000)
 Weariness Not accept
Accept 2-3 weeks
Accept in the long term
86 (22.8%)
256 (67.9%)
35 (9.3%)
558 (35.3%)
841 (53.2%)
183 (11.6%)
27.624 (0.000)
 Drug addiction Not accept
Accept 2-3 weeks
Accept in the long term
119 (32.3%)
176 (47.8%)
73 (19.8%)
367 (23.8%)
529 (34.4%)
644 (41.8%)
61.224 (0.000)
 Tremor Not accept
Accept 2-3 weeks
Accept in the long term
196 (51.9%)
167 (44.2%)
15 (4.0%)
769 (48.6%)
718 (45.5%)
95 (6.0%)
3.005 (0.223)
reluctant to accept side effects due to psychopharmacological treat-
ment than their Swiss counterparts. Acceptance of tremor did not 
yield significant differences between the two groups. 
Results of the multivariate analyses are shown in table 3. With 
respect to the social distance against people with schizophrenia, the 
origin of the MH professionals was a strong predictor when adjusted 
for sex and age. The mean score on the social distance scale was more 
than one standard deviation higher for Swiss MH professionals than 
for their counterparts in Brazil (means = 0.915 vs. -0.221 for the Swiss 
and Brazilian samples, respectively) and thus representing a very 
strong effect (Cohen’s d = 1.14). A statistically significant association 
was also found for age, suggesting that young MH professionals (aged 
up to 30) showed less social distance (mean = 0.225), whereas older 
MH professionals (aged 51 and older) reported higher social distance 
(mean = 0.496). Furthermore, a significant interaction effect between the 
origin and age of the MH professionals was observed (see figure 1). In 
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Switzerland, there were notable differences in the total social distance 
score in relation to age, whereas in Brazil the MH professionals of all 
age categories yielded almost identical values. Overall, the tests of 
between-subject effects accounted for 20.3% of total variance in the 
social distance scale, which is quite high considering that only three 
independent variables were entered into the model. 
The acceptance of side effects of psychopharmacological treat-
ment was also significantly predicted by the origin of the MH 
professionals when adjusted for sex and age; Brazilian MH profes-
sionals were less tolerant to long-term side effects in their patients 
with schizophrenia than their Swiss colleagues (means = 0.185 vs. 
-0.039 for Swiss and Brazilian MH professionals, respectively). The 
corresponding effect size was weak (Cohen’s d = 0.22). In addition, 
there was a significant effect of sex, indicating that males reported 
a higher acceptance of long-lasting side effects (means = 0.147 vs. 
0.000 for males and females, respectively), and a significant effect of 
the interaction of age and sex. As shown in figure 2, males reported 
higher acceptance in the youngest (up to 30 years) and in the two 
oldest age groups (41 years and more), whereas females reported 
higher acceptance in the age group of 31-40 years. However, the 
overall model explained only 2.0% of total variance, suggesting 
that the origin, sex and age of MH professionals show only a slight 
correlation with the acceptance of side effects. 
The social distance towards persons with schizophrenia and the 
acceptance of side effects of psychopharmacological treatment in 
persons with schizophrenia were uncorrelated. This finding applies 
to the total sample (Pearson r = 0.032, P = 0.166) as well as to the 
separate Swiss (Pearson r = 0.034, P = 0.534) and Brazilian samples 
(Pearson r = -0.005, P = 0.848). 
Discussion
This is the first study comparing attitudes of MH professionals to-
wards persons with schizophrenia in Switzerland and Brazil. We used 
multivariate models that adjusted for sex and age and we additionally 
examined interaction effects. Results show that the socio-cultural 
background may have an important effect on stigma towards indi-
viduals with schizophrenia.
Swiss MH professionals reported a consistently higher social 
distance towards individuals with schizophrenia than their Brazilian 
counterparts. The difference between the two groups was higher when 
the questions pertained to a more distant contact; on the other hand, 
questions relating to a closer contact showed a lesser difference. We 
also computed multivariate models controlling for sex and age and 
found significant effects for the origin, age as well as for the interac-
tion of origin and age of the MH professionals. The origin of the MH 
professionals had a considerably strong effect on the social distance 
towards persons with schizophrenia. The effect size was large and 
the model explained more than 20% of total variance in the social 
distance scale, which is high. 
We also examined the associations between origin of MH profes-
sionals and their attitudes towards the acceptance of side effects in 
the psychopharmacological treatment of persons with schizophrenia. 
Except for drug dependence, we found that Swiss mental health 
professionals reported consistently more acceptance than their 
Brazilian colleagues. In the multivariate model we found a modest 
significant effect for origin and a weak significant effect of sex and the 
interaction of age and sex. The effect size was small and the overall 
model accordingly only explained 2% of total variance, suggesting 
that factors other than origin, sex and age contribute to the attitudes 
towards side effects of psychopharmacological treatment. 
Other studies assessed stigma from a transcultural perspective, 
e.g.21, but only few of them evaluated stigma towards individuals 
with schizophrenia in such distinct socio-cultural backgrounds. One 
recent study compared samples of pharmacy students in Australia, 
Belgium, Estonia, Finland, India, and Latvia22. The results showed 
that the extent of stigmatizing attitudes was similar across countries, 
although students from India reported the least social distance. Ano-
ther study that examined socio-culturally diverse countries using 
general population samples reported results similar to those provided 
Table 3. Multivariate analyses of social distance and acceptance of side effects of psychopharmacological treatment: effects of origin, age, and sex of 
the mental health professionals
Mean (SE) F (df) Sig.
Social distance
Origin Switzerland (N = 365)
Brazil (N = 1587)
0.915 (0.055)
-0.221 (0.023)
366.980 (1) 0.000
Age ≤ 30 (N = 388)
31-40 (N = 570)
41-50 (N = 463)
> 50 (N = 531)
0.225 (0.073)
0.322 (0.045)
0.345 (0.049)
0.496 (0.066)
2.745 (3) 0.042
Sex Male (N = 981)
Female (N = 971)
0.318 (0.047)
0.376 (0.036)
0.981 (1) 0.322
Origin*Age 2.830 (3) 0.037
Origin*Sex 0.659 (1) 0.417
Age*Sex 0.733 (3) 0.532
Origin*Age*Sex 1.260 (3) 0.287
Side effects
Origin Switzerland (N = 354)
Brazil (N = 1524)
0.185 (0.062)
-0.039 (0.026)
11.153 (1) 0.001
Age ≤ 30 (N = 372)
31-40 (N = 548)
41-50 (N = 446)
> 50 (N = 512)
0.118 (0.085)
0.135 (0.051)
0.055 (0.056)
-0.014 (0.071)
4.761 (1) 0.029
Sex Male (N = 946)
Female (N = 932)
0.147 (0.054)
0.000 (0.040)
0.981 (1) 0.322
Origin*Age 0.606 (3) 0.611
Origin*Sex 0.260 (1) 0.610
Age*Sex 3.031 (3) 0.028
Origin*Age*Sex 2.041 (3) 0.106
119Hengartner MP, et al. / Rev Psiq Clín. 2012;39(4):115-21
respectively. A Gini coefficient of 0.0 denotes minimum inequality 
and a coefficient of 1.0 denotes maximum inequality according to 
the OECD). Those indices indicate that there is much more social 
inequality in Brazil with regards to social background, ethnic group 
or socio-economic status than there is in Switzerland, which is a 
rather homogenous society. However, one hypothesis could be, that 
Brazilians, accustomed to social diversity, are more tolerant and less 
socially distant from people distinct in appearance, behaviour or 
thinking such as persons with schizophrenia. 
This hypothesis fits with the findings of the International Pilot 
Study about Schizophrenia, conducted more than 30 years ago, which 
compared the outcome of these patients in several countries with 
different socio-economic backgrounds26. A more favourable outcome 
was found in patients from developing countries, once placed in a 
social context both more heterogeneous and less competitive, they 
would be less stigmatized for their illness. However, this hypothesis 
has previously been challenged27 and a growing body of evidence 
suggests that this axiom should be re-examined27. Other authors have 
emphasized the differential characteristics of cultures: they suggest 
that in Latin cultures the society is more protective and supporting 
than in Anglo-American cultures and thus less stigmatizing, which 
may also improve the course of schizophrenia28,29. A review about 
cultural influences has been provided by Bhugra30. 
In addition to taking the society’s homogeneity issue into account, 
willingness to control psychotic symptoms would be very desirable 
in Switzerland, thereby increasing MH professionals’ tolerance 
towards side effects. The only “side effect” not tolerable was drug 
addiction, possibly a consequence of the Swiss professionals’ criti-
cal attitudes towards Switzerland’s harm reduction policy for drugs. 
Switzerland, and especially the urban area of Zurich, suffered from 
the waste open drug scenes that developed in the early 1980s and in 
1991 the government started a heroin substitution programme for 
drug addicts covered by the mandatory health insurance31. However, 
all in all MH professionals from Switzerland and Brazil estimated 
the acceptance of side effects in the long term rather deprecatingly. 
That finding coincides with MH professionals’ personal reluctance 
to take antipsychotics themselves in the case of a psychotic disorder32 
or with the negative perception of psychopharmacological treat-
ment in general33,34. Interestingly, such distrust against psychotropic 
treatment closely corresponds with the negative picture drawn by 
newspaper reports35,36.
Minimum effects have been reported for age and sex variables, 
with age showing a slight correlation with greater social distance, 
possibly reflecting the fact that older professionals’ training was 
done before stigma became a main issue in mental health policies. 
Generally, men were shown to tolerate longer-term side effects than 
women, possibly because of a tougher attitude towards individuals 
with schizophrenia. This relationship was only inversed in the 31-40 
years age group – it has been hypothesized that female mental health 
professionals in childbearing age are more willing to medicate these 
patients because of feelings of insecurity or fear of physical aggression. 
Furthermore, other authors have posited that the higher acceptance 
of enduring side effects reported by Swiss MH professionals might 
also be related to the more sophisticated medicaments administered – 
i. e. second generation antipsychotic drugs, which are more frequently 
used in Switzerland18. 
Our study is subject to three major limitations. First, the two 
samples were not quite comparable as regards sample procedure and 
composition. The frequency of different types of MH professions as 
described in methods is not equally distributed across the Swiss and 
Brazilian samples, in particular, the percentage of psychiatrists and 
attendants: 88.8% and 0.7%, respectively, for the Brazilian sample 
versus 17.5% and 62.7%, respectively, for the Swiss sample. Adjust-
ment for professional category was not possible, for instance because 
of few case numbers in cells of combined categories of profession and 
certain age groups. However, as reported in previous studies using 
the same data of MH professionals in Switzerland, psychiatrists show 
significantly higher levels of social distance11 or negative stereotypes10 
Figure 2. Interaction effect of sex and age in association with acceptance 
of side effects of psychopharmacological treatment in persons with schi-
zophrenia.
Figure 1. Interaction effect of origin and age in association with social 
distance against persons with schizophrenia.
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in the present study23. That is, individuals in the more developed 
country, i.e. Germany, showed a higher level of social distance from 
individuals with schizophrenia when compared to a population 
sample in Russia or Mongolia. The study conducted by Des Courtis et 
al.18, also comparing MH professionals from Switzerland and Brazil, 
although in a smaller and regional sample, found analogous results; 
MH professionals from Switzerland showed a higher level of stigma 
towards persons with a mental disorder.
Stigma is a multi-factorial construct and recent studies have tried 
to depict the complex influence that culture has on its manifesta-
tions24. Angermeyer and Schulze8 have suggested that the influence 
of media on broadcasting crimes committed by mentally ill people 
in Germany increases social distance. The present study suggests that 
the other possible factors that could be put forward are ethnical di-
versity and socio-economic inequality. Indices of ethnic and cultural 
diversity for Brazil differ widely from those for Switzerland25. Fur-
thermore, Gini coefficients of income inequality for both countries 
are also rather different (0.55 and 0.28 for Brazil and Switzerland, 
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against mentally ill people than other professionals. Thus, if the per-
centage of psychiatrists in the Swiss sample had been similar to the 
percentage in the Brazilian sample, it would even have increased the 
effects of origin found in the present study. Second, the Swiss data 
of the social distance scale had to be recoded to match the Brazilian 
data. We chose to equally match the values as described in methods. 
Nevertheless, analyses conducted using a conservative recoding 
approach (matching the values 1 and 2 with the value 1, the values 
3 and 4 with the value 2 and only the value 5 of the 5-point scale 
with the 3 of the 3-point scale) also yielded the same correlations in 
slightly different proportions, but still indicated considerably higher 
levels of social distance in Swiss professionals. Third, the Swiss data 
were collected between April 2003 and April 2004. In contrast, the 
Brazilian data were assessed in November 2009. Although the time 
span between the two samples is relatively short, we cannot exclude 
that it may have biased our results. 
In conclusion, our study suggests that cultural as well as socio-
economic factors may play a major role in modulating stigma 
manifestations towards individuals with schizophrenia. Future direc-
tions should include more research on transcultural related topics 
to determine how different societal aspects may influence stigma, 
including the extent and the modus operandi of each contribution37. 
These issues are crucial to the understanding of stigma as well as to 
the launch of worldwide anti-stigma initiatives. 
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